Genovis AB (GENOb)

Currency in SEK
20.100
-0.100(-0.50%)
Closed·
Earnings results expected in 8 days
GENOb is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
20.10020.450
52 wk Range
15.64029.800
Key Statistics
Prev. Close
20.2
Open
20.3
Day's Range
20.1-20.45
52 wk Range
15.64-29.8
Volume
63.3K
Average Volume (3m)
88.38K
1-Year Change
0.9036%
Book Value / Share
4.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GENOb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.333
Upside
+65.84%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Compare GENOb to Peers and Sector

Metrics to compare
GENOb
Peers
Sector
Relationship
P/E Ratio
56.5x20.3x−0.5x
PEG Ratio
−1.951.130.00
Price/Book
4.9x3.0x2.6x
Price / LTM Sales
10.2x3.7x3.3x
Upside (Analyst Target)
54.2%14.7%43.8%
Fair Value Upside
Unlock8.3%5.3%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.333
(+65.84% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
0.10 / 0.14
Revenue / Forecast
40.3M / 37.38M
EPS Revisions
Last 90 days

GENOb Income Statement

People Also Watch

350.00
CHEMM
+3.92%
19.86
LAGA
+0.91%
11.73
SIGNC
-0.51%
156.85
GALD
+3.36%
104.40
BRAV
-0.10%

FAQ

What Is the Genovis AB (GENOb) Stock Price Today?

The Genovis AB stock price today is 20.100 SEK.

What Stock Exchange Does Genovis AB Trade On?

Genovis AB is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Genovis AB?

The stock symbol for Genovis AB is "GENOb."

What Is the Genovis AB Market Cap?

As of today, Genovis AB market cap is 1.330B SEK.

What Is Genovis AB's Earnings Per Share (TTM)?

The Genovis AB EPS (TTM) is 0.357.

When Is the Next Genovis AB Earnings Date?

Genovis AB will release its next earnings report on Apr 28, 2026.

From a Technical Analysis Perspective, Is GENOb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Genovis AB Stock Split?

Genovis AB has split 10 times.

How Many Employees Does Genovis AB Have?

Genovis AB has 36 employees.

What is the current trading status of Genovis AB (GENOb)?

As of Apr 20, 2026, Genovis AB (GENOb) is trading at a price of 20.100 SEK, with a previous close of 20.200 SEK. The stock has fluctuated within a day range of 20.100 SEK to 20.450 SEK, while its 52-week range spans from 15.640 SEK to 29.800 SEK.

What Is Genovis AB (GENOb) Price Target According to Analysts?

The average 12-month price target for Genovis AB is 33.333 SEK, with a high estimate of 41 SEK and a low estimate of 28 SEK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +65.84% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.